Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR Therapeutics N.V. (NASDAQ: PRQR).
In May, Lilly teamed up with MiNA Therapeutics to tap its small activating RNA (saRNA) technology platform for up to five targets.
ProQR will receive an upfront payment of $20 million and an equity investment of $30 million, with up to $1.25 billion as milestone payments for five targets using its RNA platform.
ProQR’s oligonucleotide platform, dubbed Axiomer, recruits “endogenous” enzymes in the cell, called ADARs, to attach to target RNA and induce adenosine to inosine base switch.
This approach can potentially reverse more than 20,000 G to A mutations known to cause human disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.